

*Substantive*  
17 (new). A method of preparing a composition for treatment of autism, comprising the steps of:

- > providing a physiologically effective amount of a purified genomeceutical material of the type that affects expression of a DPPIV like compounds when ingested by a human in such a manner as to relieve symptoms of autism;
- > providing at least one of a purified protease, a purified peptidase that exhibits DPPIV like activity or a purified phytase; and
- > mixing said purified genomeceutical and said one of said purified protease, peptidase or phytase to achieve a "compound" effective in treating symptoms of autism.

*Q*  
18 (new). The method of claim 17, wherein the step of providing at least one of a purified protease, peptidase or phytase includes the steps of providing said purified peptidase.

19 (new). The method of claim 17, wherein said step of providing a purified genomeceutical includes the step of providing at least one of purified galactose and purified glucans.

20 (new). The method of claim 17, wherein said step of providing a purified protease includes the step of providing at least one of a purified acid fast protease and a purified cystein protease.

#### REMARKS

The amendments herein are submitted prior to Examination. They include corrections of typographical errors, additional background information, claim amendments and additional claims, and amendments to the specification to provide definition of some terms used in the claims.

Applicant respectfully submits that claims 1-20 are now in condition for allowance and early notification of same is respectfully requested. Should the Examiner believe that a telephone conference would help further prosecution of this case, the Examiner is requested to contact the undersigned at 503.248.0100.